Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059380 | 1.00 | CA1 (0.53) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL4032796 | 1.00 | CA1 (0.53) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL19227630 | 0.91 | CA1 (0.58) | CA1CA2CA7CTSKCTSL | |
| Tetrahydrofuran SCHEMBL28903227 | 0.88 | CTSK (0.47) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL13520371 | 0.88 | CA1 (0.47) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL6474347 | 0.88 | CA1 (0.47) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL6169919 | 0.88 | CA1 (0.47) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL12119817 | 0.88 | CA1 (0.47) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL20745544 | 0.88 | CA1 (0.47) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL1552535 | 0.88 | CA1 (0.47) | CA1CA2CA7CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | claimed |
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | claimed |
| US-6132499-A | Inks | XEROX CORPORATION (US) | 2000-10-17 | — | — | US | claimed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | claimed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| US-6071333-A | Ink compositions | XEROX CORPORATION (US) | 2000-06-06 | — | — | US | claimed |
| US-6066200-A | COMPRISING A SOLID UREA COMPOUND, AN ALCOHOL, A LIGHTFASTNESS COMPONENT, A LIGHTFAST ANTIOXIDANT, AND A COLORANT | XEROX CORPORATION (US) | 2000-05-23 | — | — | US | claimed |
| US-5922117-A | Ink compositions containing alcohols | XEROX CORPORATION (US) | 1999-07-13 | — | — | US | claimed |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-12404294-B2 | Glycolipopeptide biosurfactants | CRODA INTERNATIONAL PLC (GB) | 2025-09-02 | — | — | US | disclosed |
| US-20250110407-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD, AND RESIST BASE FILM FORMING COMPOSITION | JSR CORPORATION (JP) | 2025-04-03 | — | — | US | disclosed |
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-5122610-A | Renin inhibitor intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-16 | — | — | US | disclosed |
| US-4997950-A | Antisecretory | MURPHY RICHARD FINBAR (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0356796-A2 | Aminomethyl peptides, production process and their use as medicaments | BAYER AG (DE) | 1990-03-07 | — | — | EP | disclosed |
| US-4885292-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0326364-A2 | Renin inhibitory oligopeptides, their preparation and use | Sankyo Company Limited (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0231919-A2 | N-Heterocyclic alcohol renin inhibitors | E.R. Squibb & Sons, Inc. (US) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404294-B2 | Glycolipopeptide biosurfactants | LYPLAL1, LNPEP, PHOSPHO1 | CA1 3612/4885CA2 3800/4885CA7 3864/4885 |
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | CA1 1188/4885CA2 306/4885CA7 3394/4885 |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | CA1 4716/4885CA2 4382/4885CA7 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.